Free Trial
→ The Iran War Isn’t Chaos. It’s Strategy. (From Behind the Markets) (Ad)tc pixel Free ESLAW Stock Alerts

Estrella Immunopharma (ESLAW) Competitors

Estrella Immunopharma logo
$0.05 0.00 (0.00%)
As of 10/13/2026
Compare

ESLAW vs. ALVOW, APLMW, ARAV, BIAFW, and BIVIW

Should you buy Estrella Immunopharma stock or one of its competitors? Estrella Immunopharma's main competitors and comparable companies include Alvotech (ALVOW), Apollomics (APLMW), Aravive (ARAV), bioAffinity Technologies (BIAFW), and BioVie (BIVIW). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Estrella Immunopharma compare to Alvotech?

Alvotech (NASDAQ:ALVOW) and Estrella Immunopharma (NASDAQ:ESLAW) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, media sentiment, analyst recommendations, valuation and risk.

In the previous week, Alvotech had 3 more articles in the media than Estrella Immunopharma. MarketBeat recorded 4 mentions for Alvotech and 1 mentions for Estrella Immunopharma. Estrella Immunopharma's average media sentiment score of 1.82 beat Alvotech's score of 0.91 indicating that Estrella Immunopharma is being referred to more favorably in the news media.

Company Overall Sentiment
Alvotech Positive
Estrella Immunopharma Very Positive

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alvotech$491.95MN/AN/AN/AN/A
Estrella ImmunopharmaN/AN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
AlvotechN/A N/A N/A
Estrella Immunopharma N/A N/A N/A

Summary

Alvotech beats Estrella Immunopharma on 2 of the 3 factors compared between the two stocks.

How does Estrella Immunopharma compare to Apollomics?

Apollomics (NASDAQ:APLMW) and Estrella Immunopharma (NASDAQ:ESLAW) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, earnings, media sentiment, analyst recommendations, institutional ownership and profitability.

Company Net Margins Return on Equity Return on Assets
ApollomicsN/A N/A N/A
Estrella Immunopharma N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Apollomics$8.50MN/AN/AN/AN/A
Estrella ImmunopharmaN/AN/AN/AN/AN/A

In the previous week, Apollomics and Apollomics both had 1 articles in the media. Estrella Immunopharma's average media sentiment score of 1.82 beat Apollomics' score of 1.79 indicating that Estrella Immunopharma is being referred to more favorably in the news media.

Company Overall Sentiment
Apollomics Very Positive
Estrella Immunopharma Very Positive

Summary

Apollomics and Estrella Immunopharma tied by winning 1 of the 2 factors compared between the two stocks.

How does Estrella Immunopharma compare to Aravive?

Estrella Immunopharma (NASDAQ:ESLAW) and Aravive (NASDAQ:ARAV) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, dividends, profitability, risk and valuation.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Estrella ImmunopharmaN/AN/AN/AN/AN/A
AraviveN/AN/AN/A-$0.90N/A

In the previous week, Estrella Immunopharma had 1 more articles in the media than Aravive. MarketBeat recorded 1 mentions for Estrella Immunopharma and 0 mentions for Aravive. Estrella Immunopharma's average media sentiment score of 1.82 beat Aravive's score of 0.00 indicating that Estrella Immunopharma is being referred to more favorably in the media.

Company Overall Sentiment
Estrella Immunopharma Very Positive
Aravive Neutral

35.8% of Aravive shares are owned by institutional investors. 60.4% of Aravive shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Company Net Margins Return on Equity Return on Assets
Estrella ImmunopharmaN/A N/A N/A
Aravive N/A N/A N/A

Summary

Estrella Immunopharma and Aravive tied by winning 2 of the 4 factors compared between the two stocks.

How does Estrella Immunopharma compare to bioAffinity Technologies?

Estrella Immunopharma (NASDAQ:ESLAW) and bioAffinity Technologies (NASDAQ:BIAFW) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, risk, profitability, earnings, valuation and dividends.

Company Net Margins Return on Equity Return on Assets
Estrella ImmunopharmaN/A N/A N/A
bioAffinity Technologies N/A N/A N/A

In the previous week, bioAffinity Technologies had 4 more articles in the media than Estrella Immunopharma. MarketBeat recorded 5 mentions for bioAffinity Technologies and 1 mentions for Estrella Immunopharma. Estrella Immunopharma's average media sentiment score of 1.82 beat bioAffinity Technologies' score of 0.42 indicating that Estrella Immunopharma is being referred to more favorably in the media.

Company Overall Sentiment
Estrella Immunopharma Very Positive
bioAffinity Technologies Neutral

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Estrella ImmunopharmaN/AN/AN/AN/AN/A
bioAffinity Technologies$5.85MN/AN/AN/AN/A

Summary

bioAffinity Technologies beats Estrella Immunopharma on 2 of the 3 factors compared between the two stocks.

How does Estrella Immunopharma compare to BioVie?

Estrella Immunopharma (NASDAQ:ESLAW) and BioVie (NASDAQ:BIVIW) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, institutional ownership, valuation, risk, analyst recommendations, profitability, dividends and earnings.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Estrella ImmunopharmaN/AN/AN/AN/AN/A
BioVieN/AN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
Estrella ImmunopharmaN/A N/A N/A
BioVie N/A N/A N/A

In the previous week, BioVie had 1 more articles in the media than Estrella Immunopharma. MarketBeat recorded 2 mentions for BioVie and 1 mentions for Estrella Immunopharma. Estrella Immunopharma's average media sentiment score of 1.82 beat BioVie's score of 1.41 indicating that Estrella Immunopharma is being referred to more favorably in the media.

Company Overall Sentiment
Estrella Immunopharma Very Positive
BioVie Positive

Summary

Estrella Immunopharma and BioVie tied by winning 1 of the 2 factors compared between the two stocks.

Get Estrella Immunopharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for ESLAW and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ESLAW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ESLAW vs. The Competition

Export
MetricEstrella ImmunopharmaBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market CapN/A$3.88B$7.26B$13.10B
Dividend YieldN/A3.65%2.52%22.89%
P/E RatioN/A13.21275.5425.58
Price / SalesN/A1,131.68557.6780.26
Price / CashN/A118.5077.1653.04
Price / BookN/A17.1610.816.02
Net IncomeN/A-$22.65M$3.49B$380.34M
7 Day PerformanceN/A-4.64%-3.00%-3.19%
1 Month PerformanceN/A-12.66%-7.48%-6.07%
1 Year PerformanceN/A8.08%3.18%-3.77%

Estrella Immunopharma Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ESLAW
Estrella Immunopharma
N/A$0.05
flat		N/AN/A$0.00N/AN/AN/A
ALVOW
Alvotech
N/A$0.26
-1.8%		N/A-70.0%$0.00$491.95MN/A4
APLMW
Apollomics
N/A$0.01
-21.6%		N/AN/A$0.00$8.50MN/A15
ARAV
Aravive
N/A$0.04
flat		N/AN/A$0.00N/AN/A20
BIAFW
bioAffinity Technologies
N/A$0.40
+25.9%		N/A-29.4%$0.00$5.85MN/A10

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:ESLAW) was last updated on 10/14/2026 by MarketBeat.com Staff.
From Our Partners
The AI Infrastructure Play Kevin O'Leary Is Backing
Kevin O'Leary became a strategic investor in a NASDAQ-listed AI infrastructure company, calling it essentially...
The Tomorrow Investor | Sponsoredtc pixel
Elon Musk’s One Stock Retirement Plan
Jeff Brown picked Nvidia in 2016, before it surged 37,000 percent. Now he's tracking a small AI company he say...
Brownstone Research | Sponsoredtc pixel
Wall Street legend reveals his top AI stock before Oct. 20
Marc Chaikin, the 60-year Wall Street veteran behind the Power Gauge rating system, has flagged a new AI stock...
Chaikin Analytics | Sponsoredtc pixel
How one AI fund pays investors every Thursday
One small fund tied to artificial intelligence stocks delivered $1,051 in a single month, not through selling ...
Investors Alley | Sponsoredtc pixel
AI Microcap Teams With Gentex on Next-Gen Military Helmets
Morgan Stanley projects the humanoid robotics market could reach $5 trillion by 2050, with more than 1 billion...
Capital Trends | Sponsoredtc pixel
Federal Reserve Reveals Disturbing New Plan To Control Your Money
Docket No. OP-1670 is drawing attention for what it reveals about the Federal Reserve's next move. Buried on p...
Weiss Ratings | Sponsoredtc pixel
Trump's about to unleash his Midterm Weapon
Trump is turning the midterms into a referendum on American energy, pushing for more oil, more gas, and lower ...
Monument Traders Alliance | Sponsoredtc pixel
The Iran War Isn’t Chaos. It’s Strategy.
Two thousand missiles struck Iran. Three days later, Dylan Jovine sat in two private meetings with U.S. Congre...
Behind the Markets | Sponsoredtc pixel